

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**BEIJING TONG REN TANG CHINESE MEDICINE COMPANY LIMITED**

北京同仁堂國藥有限公司

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 3613)**

**VOLUNTARY ANNOUNCEMENT  
INCREASE IN SHAREHOLDING BY DIRECTORS**

This announcement is made by Beijing Tong Ren Tang Chinese Medicine Company Limited (the “**Company**”) on a voluntary basis.

The board of directors (the “**Board**”) of the Company was informed by Ms. Ding Yong Ling (“**Ms. Ding**”), the chairman of the Board and the executive director of the Company, Mr. Chen Fei (“**Mr. Chen**”), the chief executive officer and the executive director of the Company, and Ms. Lin Man (“**Ms. Lin**”), the chief operating officer and the executive director of the Company, that during the period of 16 and 17 August 2022, each of Ms. Ding, Mr. Chen and Ms. Lin acquired 20,000 shares of the Company (the “**Shares**”) on the market for an aggregate consideration of approximately HK\$181,600 (representing an average price of approximately HK\$9.080 per Share), HK\$184,100 (representing an average price of approximately HK\$9.205 per Share) and HK\$182,800 (representing an average price of approximately HK\$9.140 per Share) (collectively the “Share Purchases”) respectively.

As at the date of this announcement and after the Share Purchases, Ms. Ding holds a total of 430,000 Shares, representing approximately 0.051% of the total number of Shares in issue; Mr. Chen holds a total of 42,000 Shares, representing approximately 0.005% of the total number of Shares in issue; Ms. Lin holds a total of 310,000 Shares, representing approximately 0.037% of the total number of Shares in issue. The Share Purchases fully demonstrate Ms. Ding, Mr. Chen and Ms. Lin’s confidence in the overall development prospects and growth potential of the Company.

Based on the information available to the Company and to the best knowledge of the Board, the Company has maintained sufficient public float of the issued Shares immediately following the Share Purchases and as at the date of this announcement.

By order of the Board  
**Beijing Tong Ren Tang**  
**Chinese Medicine Company Limited**  
**Ding Yong Ling**  
*Chairman*

Hong Kong, 17 August 2022

As at the date of this announcement, the composition of the Board is as follows:

***Executive Directors:***

Ms. Ding Yong Ling (*Chairman*)  
Mr. Chen Fei  
Ms. Lin Man  
Ms. Feng Li

***Independent Non-executive Directors:***

Mr. Tsang Yok Sing, Jasper  
Mr. Zhao Zhong Zhen  
Mr. Chan Ngai Chi